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Abstract
Introduction—Studies have demonstrated that intravenous recombinant tissue plasminogen 
activator (IV rtPA) is a cost-effective treatment for acute ischemic stroke. Age-specific cost 
effectiveness has not been well examined. This study estimated age-specific incremental cost-
effectiveness ratios (ICERs) of IV rtPA treatment versus no IV rtPA.
Methods—A Markov model was developed to examine the economic impact of IV rtPA over a 
20-year time horizon on four age groups (18–44, 45–64, 65–80, and ≥81 years) from the U.S. 
healthcare sector perspective. The model used health outcomes from a national stroke registry 
adjusted by parameters from previous literature and current hospitalization costs in 2013 U.S. 
dollars. Long-term annual costs and quality-adjusted life years (QALYs) in the years after a stroke 
were discounted at 3% per year. Incremental costs, incremental QALYs, and ICERs were 
estimated and sensitivity analyses were conducted between 2015 and 2017.
Results—Use of IV rtPA gained 0.55 QALYs and cost $3,941 more than no IV rtPA for stroke 
patients aged ≥18 years over a 20-year time horizon. IV rtPA was a dominant strategy compared to 
no IV rtPA for patients aged 18–44 and 45–64 years. For patients aged 65–80 years, IV rtPA 
gained 0.44 QALYs and cost $4,872 more than no IV rtPA (ICER=$11,132/QALY). For patients 
aged ≥81 years, ICER was estimated at $48,676/QALY.
Conclusions—IV rtPA saved costs and improved health outcomes for patients aged 18–64 years 
and was cost effective for those aged ≥65 years. These findings support the use of IV rtPA.
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INTRODUCTION
Stroke is a serious disease with high costs and high rates of death and disability. About 6.6 
million U.S. adults have had a stroke, and the cost of stroke in the U.S. was $33 billion in 
2012.1 Intravenous recombinant tissue plasminogen activator (IV rtPA, alteplase), the only 
intravenous or intra-arterial medication approved by the U. S. Food and Drug 
Administration, is recommended for treatment of acute ischemic stroke by the American 
Heart Association and American Stroke Association (AHA/ASA).2
Previous research has shown that IV rtPA is a cost-saving or cost-effective treatment.3–8 For 
example, a 1998 study showed that IV rtPA is a cost-saving treatment.3 A more recent study 
published in 2014 by Boudreau et al.4 confirmed that the use of IV rtPA within 3 hours after 
stroke onset saved costs and improved health outcomes. In 2009, AHA/ASA guidelines were 
updated to recommend the use of IV rtPA between 3 and 4.5 hours after an acute ischemic 
stroke onset.9 Two subsequent studies showed that IV rtPA injection between 3 and 4.5 
hours after stroke onset was cost effective.6,8
Although evidence exists that IV rtPA is a cost-saving or cost-effective treatment within both 
of the time frames described, the cost effectiveness of this treatment for people of different 
ages has not been thoroughly examined. Using data from a national stroke registry and 
information about current hospitalization costs, this study estimates the age-specific 
incremental cost-effectiveness ratios (ICERs) of IV rtPA treatment compared to no IV rtPA 
in the U.S.
METHODS
The Models
Based on a Markov model from Boudreau and colleagues,4 a decision tree model was 
developed for this study. A U.S. healthcare sector perspective with a 20-year time horizon 
was used.10 All costs were reported in 2013 U.S. dollars. Costs were adjusted by using 
Medical Care Consumer Price Index data from the U.S. Bureau of Labor Statistics, if 
needed.4,11 All health outcomes and costs were discounted at a 3% rate.12 All analyses with 
the decision tree model were performed in TreeAge Pro, version 2016, between 2015 and 
2017.
A decision tree was adapted to simulate health status 3 months after discharge from 
hospitalization for acute ischemic stroke (Figure 1).4,8,13 Possible outcomes were 
nondisabled, disabled, and death. The modified Rankin Scale, which is used to measure the 
level of disability of stroke patients, was used to define these outcomes. Specifically, scores 
0–2 were used for the outcome of nondisabled (no or minor disability), scores 3–5 were used 
for the outcome of disabled (moderate to severe disability), and a score of 6 was used for the 
outcome of death.14 For patients who were nondisabled or disabled 3 months after 
discharge, a Markov model was used to simulate long-term health status and change in 
health status because of a recurrent stroke or non-stroke death over a 20-year time horizon.10 
Time cycle in the model was 1 year.15,16 Patients stayed at their original health status until 
they experienced a recurrent stroke or non-stroke death.4,8 Patients who had a recurrent 
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stroke could move to the disabled or death health status. This study assumed that patients 
with recurrent stroke do not receive IV rtPA and that patients cannot move from disabled to 
nondisabled health status.4,8 Models were generated for patients in four age groups: 18–44, 
45–64, 65–80, and ≥81 years.
Data
Data on the health status of patients were taken from the Paul Coverdell National Acute 
Stroke Program (PCNASP) for 2012–2013. The PCNASP tracks and measures acute stroke 
care in the U. S. and works to improve the quality of care for stroke patients.17 It is funded 
and supported by the U.S. Centers for Disease Control and Prevention.17 This study defined 
the IV rtPA group as patients who received IV rtPA at the PCNASP reporting hospitals. The 
no IV rtPA group was defined as follows: (1) IV rtPA was not initiated for the patient at the 
reporting hospital, (2) no IV rtPA was initiated at an outside reporting hospital, and (3) no 
intra-arterial catheter-based reperfusion was given at the reporting hospital.
Since the PCNASP is not an RCT but a registry, characteristics of patients in the IV rtPA 
group and the no IV rtPA group were significantly different. For example, patients in the IV 
rtPA group were younger and typically had experienced a more severe stroke than those in 
the no IV rtPA group. Because this study was designed to compare patients who received IV 
rtPA to those who could have received this treatment but did not, a propensity score 
matching technique was used to match the characteristics of the two groups. Patients’ age, 
gender, and stroke severity, using the NIH Stroke Scale, were controlled.18 Although 
propensity score matching has a disadvantage that any bias associated with latent covariates 
may endure even after the matching,19 propensity score matching is a common approach to 
evaluate effects of treatment.20 NIH Stroke Scale characterizes the initial evaluation of 
stroke patients before treatment. The percentages of patients in each group who were 
nondisabled or disabled or who died during hospitalization by IV rtPA status were compared 
using matched samples (N=7,418).
This study estimated the probabilities of being disabled or dying at 3 months after discharge 
by using the PCNASP data that included the probabilities of being disabled or dying during 
hospitalization and the previous literature (Table 1).3 An extrapolation technique was used 
for the estimations. The validity of categorization of modified Rankin Scale was guaranteed 
by a similar distribution of modified Rankin Scale scores within each category between IV 
rtPA and no IV rtPA groups.4,8
This study applied age-specific baseline mortality from the U.S. life tables21 to the Markov 
model for patients at 3 months after a stroke. For patients who were nondisabled or disabled, 
mortality was adjusted using the mortality hazard ratio from previous literature.22,23
Costs of acute care for acute ischemic stroke during initial hospitalization were estimated by 
using the 2010–2013 Market-Scan Commercial Claims and Encounters Inpatient Database 
and Medicare Supplemental and Coordination of Benefits Database.24,25 This database has 
been used to analyze the costs of ischemic stroke, and the authors’ cost estimates were 
consistent with the literature.24,26–29 This study applied the estimated age-specific acute care 
costs using the database. The cost for patients who were nondisabled was defined as the 
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average per person inpatient payment for patients discharged to home after hospitalization. 
The cost for patients who were disabled was defined as the payment for those discharged to 
any destination except home. The cost for patients who died was defined as the average per 
person inpatient payment for patients who died at a hospital. These definitions came from 
Earnshaw et al.30 Annual costs beginning at 3 months after a stroke for nondisabled and 
disabled patients are taken from the previous literature.30
Quality-adjusted life years (QALYs) were used as a measure of health outcome. Estimates of 
mean QALYs for nondisabled and disabled stroke patients were taken directly from a 
previous study.4
Sensitivity Analysis
One-way sensitivity analyses as well as probabilistic sensitivity analyses were performed to 
confirm the robustness of the cost-effectiveness results. One-way sensitivity analyses were 
conducted with each input using ranges shown in Tables 1 and 2. Input parameters for the 
top ten causes of variability in ICERs are shown in tornado diagrams by age group. This 
study reported 95% CIs for each health outcome and developed cost-effectiveness 
acceptability curves using the results of probabilistic sensitivity analyses. The curves 
demonstrated the probability of IV rtPA being cost effective compared to no IV rtPA at a 
range of willingness-to-pay per QALY, which is called the cost-effectiveness threshold. This 
study used $50,000 per QALY and $100,000 per QALY as cost-effectiveness thresholds.32,33 
Technical details about probabilistic sensitivity analyses are presented in the Appendix 
(available online).
RESULTS
Use of IV rtPA increased QALYs and decreased costs for patients aged 18–44 and 45–64 
years (Table 3). For patients aged 65–80 and ≥81 years, IV rtPA increased both QALYs and 
costs. ICERs were $11,132 per QALY for those aged 65–80 years (95% CI= −$821, $41,255 
per QALY) and $48,676 per QALY for those aged ≥81 years (95% CI= −$488,562, 
$537,997 per QALY). For all patients aged ≥18 years, ICER was $7,134 per QALY (95% 
CI= −$7,057, $59,807 per QALY).
In the one-way sensitivity analyses, models for patients aged 18–44, 65–80, and ≥81 years 
were most sensitive to the probability of death for no IV rtPA group (Appendix Figure 1, 
available online). The probability of death for IV rtPA group had the largest effect on the 
models for patients aged 45–64 years. In the probabilistic sensitivity analyses, results of 
ICERs by each age group were examined using cost-effectiveness acceptability curves 
(Appendix Figure 2, available online). The curves for two age groups, aged 18–44 and 45–
64 years, showed a 100% probability that IV rtPA treatment was cost effective at the 
$50,000 per QALY threshold. In other words, based on the model, the additional cost of IV 
rtPA treatment compared with no IV rtPA is always less than $50,000 per QALY for those 
age groups. For patients aged 65–80 years, there was a 97% probability that IV rtPA was 
cost effective at $50,000 per QALY and a 98% probability that it was cost effective at 
$100,000 per QALY. For patients aged ≥81 years, the cost-effectiveness acceptability curves 
demonstrated a 47% probability that IV rtPA was cost effective at $50,000 per QALY. In 
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other words, there was a 47% probability that the cost of IV rtPA compared with no IV rtPA 
was less than $50,000 per QALY. For this age group, there was a 75% probability that IV 
rtPA was cost effective at $100,000 per QALY. For all age groups, the probability that IV 
rtPA is cost effective is 96% at $50,000 per QALY and 99% at $100,000 per QALY.
DISCUSSION
This study demonstrated that IV rtPA was either a costsaving or cost-effective strategy for 
treating patients with acute ischemic stroke, but that ICERs varied by age. Overall, ICER 
was $7,134 per QALY for patients who received IV rtPA compared with those who did not. 
These findings are consistent with previous research.3,4,8 In the U.S., the use of IV rtPA 
within 3 hours after stroke onset is known to be a cost-saving treatment, whereas the use of 
IV rtPA between 3 and 4.5 hours after stroke onset is a cost-effective approach.3,4,8 
Boudreau and colleagues8 have also shown that IV rtPA between 3 and 4.5 hours after stroke 
onset is cost saving for people aged <65 years. The findings from this study confirm that IV 
rtPA is a cost-saving treatment for patients aged 18–44 and 45–64 years. A Chinese study of 
the cost effectiveness of IV rtPA treatment within 4.5 hours of stroke onset showed that this 
treatment led to an ICER of $2,380 per QALY gained in a 30-year time horizon.13
For patients who could be treated with IV rtPA within 3 to 4.5 hours after stroke onset, the 
effectiveness of IV rtPA was not ascertained for patients aged >80 years in the 2013 
AHA/ASA guideline.2 The 2016 AHA/ASA guideline, however, suggested that IV rtPA for 
patients aged >80 years can be as effective as in younger patients.34 The Food and Drug 
Administration label for rtPA still mentions that the risks of IV rtPA treatment may increase 
for patients aged >75 years, and the treatment should be initiated within 3 hours.34 Baseline 
results showed that IV rtPA treatment was still cost effective for patients >80 years, using a 
$50,000 per QALY threshold. However, the probabilistic sensitivity analysis predicted cost 
effectiveness of IV rtPA in 47% of simulation runs with the same threshold. This study also 
found that about 29% of patients in the 2012–2013 PCNASP who received IV rtPA were 
older than 80 years. As the U.S. population continues to age, improving access to IV rtPA 
among elderly stroke patients will become a significant public health issue.
Developing stroke systems of care that include emergency medical service partners, 
developing protocols for IV rtPA delivery, and expanding the use of telemedicine and 
helicopter transport for stroke patients could improve access to IV rtPA, assuming that 
patients activate emergency care in a timely manner.35–37 However, these strategies might 
require additional costs, which were not considered in the current study.17,36,38 For instance, 
to help build state-based stroke registries as part of the PCNASP, the U.S. Centers for 
Disease Control and Prevention funded six state health departments (Georgia, 
Massachusetts, Michigan, Minnesota, North Carolina, and Ohio) about $600,000 annually 
from 2007 to 2012.17 Future research could assess the costs needed to implement programs 
that improve access to IV rtPA.
Since 2015, treatment for large vessel occlusions with mechanical endovascular reperfusion 
(MER) has emerged as a standard of care for selected patients.2,39–43 In appropriate patients, 
MER has been shown to reduce disability and mortality.39–43 However, AHA/ASA 
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recommends that patients who are eligible for IV rtPA should receive the treatment, even if 
they receive MER later.2 Early studies demonstrated that for some patients IV rtPA +MER is 
a lifetime dominant strategy in a Swedish setting compared to the standard of care (IV rtPA 
only).44 In the U.S. setting, MER treatment within the 0 to 6-hour window after IV rtPA 
within 0 to 4.5-hour window is a lifetime cost-effective strategy for 65-year-old patients with 
acute ischemic stroke caused by a proximal intracranial occlusion.45
This study has several strengths. First, it used national registry data to examine the cost 
effectiveness of IV rtPA treatment in a real-world setting, which was identified as a research 
gap.4 Thus, the results could provide reasonable parameters for further economic evaluations 
of public health programs that support IV rtPA treatment. Another strength is the use of 
current data. MarketScan data for 2010–2013 were used to estimate acute care costs for 
stroke patients, and the PCNASP data for 2012–2013 were used to estimate health 
outcomes. Both the MarketScan database and the PCNASP data have information about a 
large number of stroke patients.24 This study also used recognized modeling techniques, 
Markov models for recursive disease process simulation.46 This study also provided results 
from one-way and probabilistic sensitivity analyses, which supported the robustness of the 
findings. Another strength of this analysis is that it showed that the age of the patient could 
affect the cost effectiveness of IV rtPA treatment in the U.S. Investigation of variances by 
age and ways to improve the cost-effectiveness ratio for particular age groups is an 
important area for future research.
Limitations
This study also has several limitations. Although sample characteristics between the IV rtPA 
and no IV rtPA groups were matched, there could be other factors that affected health 
outcomes after stroke onset (e.g., baseline pre-stroke disability, the presence of serious 
comorbidities) but these factors could not be accounted for. This study also did not consider 
the time window of when IV rtPA was injected because of data limitation. However, it is 
reasonable to assume that data from a national stroke registry in 2012–2013 represents 
patients who received IV rtPA within 0 to 4.5 hours after stroke onset and is not limited to 
those who received IV rtPA within 0 to 3 hours after stroke onset. It is because the data were 
collected after AHA/ASA released its extended time window recommendation in 2009.9 
Still, some patients may have received IV rtPA after 4.5-hour time window. Late treatment 
might decrease the health benefits of IV rtPA among the IV rtPA group.
Although this study attempted to use most plausible data, some input parameters may have 
an issue with possible bias. For instance, use of the Medical Care Consumer Price Index for 
inflation adjustment has been reported to be a biased measure of overall medical inflation.47 
However, the index is still widely used. Also, using payment data as a proxy for acute 
treatment costs is a limitation of this study, because payments by private insurers may 
exceed the costs of providing care and are also generally higher than Medicare payments. 
This study used input parameters, such as QALYs and a mortality rate, from different 
sources, which may not necessarily be consistent. The Markov model is limited because the 
history of a disease cannot affect its prognosis with the model.46 An RCT, which can 
provide the strongest evidence of the treatment efficacy, could be an alternative. However, 
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because long-term RCT data including both efficiency and costs information are not 
available, a simulation model is the best possible option. A stroke patient with recurrent 
strokes may have higher annual costs after discharge and a higher mortality rate than a 
patient with a first-ever stroke. The Markov model also did not consider the time 
dependency of input parameters. This study allowed variations by age in the efficacy of 
acute care and prognosis only up to 3 months after stroke onset because of limited data. 
However, cost effectiveness could vary by age because of other age-related factors, such as 
treatment efficacy after 3 months, and annual treatment costs after discharge. Thus, the 
variation of ICERs by age may be underestimated.
CONCLUSIONS
This is the first study to demonstrate the cost effectiveness of IV rtPA using the real-world 
registry data in the U.S. The findings in this study provide age-specific information about 
the cost effectiveness of IV rtPA treatment for patients who experience an acute ischemic 
stroke. IV rtPA treatment saves money and improves health outcomes for stroke patients 
aged 18–64 years. For patients aged ≥65 years, IV rtPA treatment is a cost-effective strategy 
compared to no IV rtPA. These findings, which used current data in a real-world setting, 
support the importance of promoting IV rtPA treatment for stroke patients for all adults of all 
ages.
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Figure 1. 
Decision tree for cost-effectiveness analyses of IV rtPA use for patients with acute ischemic 
stroke.
IV rtPA, intravenous recombinant tissue plasminogen activator.
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Table 1
Probabilities of Health Status of Acute Ischemic Stroke Patients at 3 Months After Hospital Discharge, by Age
Age group/health status No IV rtPA group, % (95% CI) IV rtPA group, % (95% CI)
18–44 years
 Disabled 39 (34, 42) 25 (21, 30)
 Death 10 (3, 16) 6 (1, 11)
45–64 years
 Disabled 40 (37, 41) 25 (23, 27)
 Death 19 (16, 23) 17 (13, 20)
65–80 years
 Disabled 44 (43, 46) 34 (33, 36)
 Death 27 (23, 31) 27 (23, 31)
≥81 years
 Disabled 46 (45, 48) 42 (40, 44)
 Death 42 (37, 47) 40 (35, 45)
Total
 Disabled 43 (42, 44) 33 (32, 34)
 Death 28 (26, 30) 27 (24, 29)
Note: Health status defined by mRS (scores 3–5 for disabled and 6 for death). Because data on mRS were only collected at hospital discharge from 
the PCNASP, probabilities at discharge from the PCNASP were adjusted to probabilities at 3 months after stroke onset by using the ratios from 
Fagan et al.3.
IV rtPA, intravenous recombinant tissue plasminogen activator; mRS, modified Rankin Scale.
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Table 2
Clinical Parameters, Costs, and Health Outcomes Used in the Cost-Effectiveness Model
Inputs Parameters for baselinea
Parameters for probabilistic sensitivity 
analyses
ReferenceM (SD) Distribution
Annual clinical parameters
 Probabilities of stroke 
recurrence
0.0498 (0.0446–0.055) 0.050 (0.002) β Hong et al.31
 Mortality hazard ratio: 
nondisabled
1.1 (1–1.7) 1.183 (0.117) Normal Stahl et al.,22 Boudreau et al.4
 Mortality hazard ratio: 
disabled
2.5 (1.7–3.8) 2.583 (0.350) Normal Eriksson et al.23
Acute care cost (2013 U.S.$)
No IV rtPA group
 18-44 years
  Nondisabled 18,215 (17,751–18,679) 18,215 (155) γ MarketScan 2010–201325
  Disabled 34,724 (32,588–36,859) 34,724 (712) γ MarketScan 2010–201325
  Death 44,658 (37,805–51,510) 44,658 (2,284) γ MarketScan 2010–201325
 45–64 years
  Nondisabled 16,163 (15,997–16,330) 16,163 (56) γ MarketScan 2010–201325
  Disabled 27,436 (26,878–27,995) 27,436 (186) γ MarketScan 2010–201325
  Death 40,105 (37,727–42,484) 40,105 (793) γ MarketScan 2010–201325
 65–80 years
  Nondisabled 13,250 (13,043–13,457) 13,250 (69) γ MarketScan 2010–201325
  Disabled 17,334 (16,980–17,687) 17,334 (118) γ MarketScan 2010–201325
  Death 23,415 (21,943–24,887) 23,415 (491) γ MarketScan 2010–201325
 ≥81 years
  Nondisabled 13,087 (12,811–13,362) 13,087 (92) γ MarketScan 2010–201325
  Disabled 15,408 (15,150–15,667) 15,408 (86) γ MarketScan 2010–201325
  Death 19,616 (18,612–20,620) 19,616 (335) γ MarketScan 2010–201325
IV rtPA group
 18–44 years
  Nondisabled 28,027 (25,899–30,155) 28,027 (709) γ MarketScan 2010–201325
  Disabled 39,764 (34,476–45,053) 39,764 (1,763) γ MarketScan 2010–201325
  Death 48,995 (27,693–70,297) 48,995 (7,101) γ MarketScan 2010–201325
 45–64 years
  Nondisabled 26,998 (26,106–27,889) 26,998 (297) γ MarketScan 2010–201325
  Disabled 40,007 (37,858–42,156) 40,007 (716) γ MarketScan 2010–201325
  Death 38,996 (32,566–45,427) 38,996 (2,144) γ MarketScan 2010–201325
 65–80 years
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Inputs Parameters for baselinea
Parameters for probabilistic sensitivity 
analyses
ReferenceM (SD) Distribution
  Nondisabled 22,728 (21,443–24,014) 22,728 (429) γ MarketScan 2010–201325
  Disabled 27,141 (25,502–28,780) 27,141 (546) γ MarketScan 2010–201325
  Death 31,629 (26,936–36,323) 31,629 (1,565) γ MarketScan 2010–201325
 ≥81 years
  Nondisabled 24,276 (22,062–26,490) 24,276 (738) γ MarketScan 2010–201325
  Disabled 24,440 (23,095–25,785) 24,440 (448) γ MarketScan 2010–201325
  Death 27,674 (24,561–30,787) 27,674 (1,038) γ MarketScan 2010–201325
Annual cost after hospital discharge (2013 U.S.$)
 Nondisabled 5,714 (4,571–6,856) 5,714 (381) γ Earnshaw et al.30
 Disabled 14,635 (11,708–17,562) 14,635 (976) γ Earnshaw et al.30
Health outcomes
 QALYs: nondisabled 0.84 (0.66–0.92) 0.823 (0.043) β Boudreau et al.4
 QALYs: disabled 0.47 (0.24–0.66) 0.463 (0.070) β Boudreau et al.4
Discount rate (%) 3 (2.4–3.6) 3 (0.2) Uniform Assumption
aNumbers in parentheses show sensitivity range for one-way sensitivity analyses. Sensitivity ranges are ±20% for discount rate and annual costs 
after hospital discharge.
IV rtPA, intravenous recombinant tissue plasminogen activator; QALYs, quality-adjusted life years.
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